United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and preliminary data from PHINDER, a first of its kind study designed to improve screening for pulmonary hypertension associated with interstitial lung disease (PH-ILD)
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona.
